Search

Home > OIS Podcast > Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease
Podcast: OIS Podcast
Episode:

Gemini CEO McLaughlin Explains How the Precision Therapeutics Start-up Will Take Aim at Eye Disease
Category: Business
Duration: 00:20:23
Publish Date: 2017-10-17 23:00:00
Description: Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemini hopes to advance the war against these dreadful diseases.
Total Play: 0